NCT02749630View on ClinicalTrials.gov

A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

February 19, 2020

Study Completion Date

February 19, 2020

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

Placebo

Matching placebo to UTTR1147A administered intravenously

DRUG

UTTR1147A

Escalating doses of intravenously administered UTTR1147A

Trial Locations (2)

10117

Charité Research Organisation GmbH, Berlin

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY